Lexicon Pharmaceuticals Inc (LXRX) - News Archive

Lexicon Pharmaceuticals Advances Toward Sotagliflozin Resubmission with Additional Data Submission to the FDA Lexicon Pharmaceuticals announced a significant update regarding its efforts to advance the approval of Zynqu...

Lexicon s Zynquista Setback: Navigating the Regulatory Maze In the complex maze of pharmaceutical regulations and approvals, Lexicon Pharmaceuticals recently encountered a significant hurdle. The U.S. Food and Drug Admi...

Lexicon Pharmaceuticals Inc. a biopharmaceutical company focused on developing innovative therapies for a range of diseases, recently announced the completion of enrollment in the Phase 2B PROGRESS study of LX9211, whic...

The burgeoning fields of obesity and cardiometabolic disease research have seen significant advancements recently, particularly in the development of novel therapeutic agents. The investigational compound LX9851 represe...

Lexicon Pharmaceuticals Faces Financial Headwinds Amid FDA Advisory Approval for Zynquista Amid a backdrop of significant financial challenges, Lexicon Pharmaceuticals Inc. recently announced the outcome of an FDA Advis...

Innovative Sotagliflozin Trial Designs and New Insights to be Unveiled by Lexicon Pharmaceuticals at Upcoming Medical Conferences Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is poised to showcase groundbreaking designs...

Unlocking New Potential: The Impact of Sotagliflozin on Diabetes Management In recent developments within diabetes pharmacotherapy, new secondary analyses stemming from Phase 3 clinical trials have showcased the potenti...

Exploring the Promise of Sotagliflozin: A Deep Dive into Efficacy and Safety for Type 1 Diabetes Patients with Chronic Kidney Disease In the landscape of diabetes management, ongoing research continues to shed light on...

Heart failure (HF) is a significant public health burden associated with high morbidity, mortality, and healthcare costs. The need for effective and cost-saving interventions is paramount, particularly in the context of...

Lexicon Pharmaceuticals Resubmits NDA for Sotagliflozin Amid Compelling New Data Lexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) for sotagliflozin, aiming to receive approval for its use as an adj...

The recent publication of Lexicons RELIEF-DPN 1 Phase 2 Study results in Diabetes Care , a peer-reviewed journal of the American Diabetes Association, has underscored the potential of LX9211 as a promising non-opioid th...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) recently made groundbreaking progress regarding the understanding and treatment of Diabetic Peripheral Neuropathic Pain (DPNP). Three poster presentations were delivered duri...

The search for novel therapeutic approaches to manage heart failure has led to significant advancements in recent years. The emerging class of sodium-glucose cotransporter 2 (SGLT2) inhibitors has revolutionized the tre...

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease Type 1 diabetes is a chronic condition char...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has recently revealed that it has entered into a securities purchase agreement for a private investment in public equity financing. The company expects to amass approximately...

aims to provide its readers with insightful articles surrounding advancements in the pharmaceutical industry. In this article, we will analyze two related publications concerning the resubmission of Sotagliflozin, a pot...

Amidst the 42nd Annual J.P. Morgan Healthcare Conference, Lexicon Pharmaceuticals made significant strides in reinforcing its position as an industry leader. With an exciting update on their business and pipeline, the c...

Lexicon Pharmaceuticals has recently announced the enrollment of the first patient in the Phase 2b PROGRESS study for LX9211—a promising AAK1 inhibitor—for the treatment of Diabetic Peripheral Neuropathic Pain (DPNP). T...